Aerie Pharmaceuticals has announced positive results of Phase 2 of its clinical study of the AR-1105 dexamethasone intravitreal implant for patients with retinal vein thrombosis. Two formulas of the drug were studied: CF-1 and CF-2. Both showed good results, the patients improved visual acuity and decreased edema of the yellow spot.